Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

Brigitte Michelsen, Ulf Lindström, Catalin Codreanu, Adrian Ciurea, Jakub Zavada, Anne Gitte Loft, Manuel Pombo-Suarez, Fatos Onen, Tore K. Kvien, Ziga Rotar, Maria Jose Santos, Florenzo Iannone, Anna-Mari Hokkanen, Bjorn Gudbjornsson, Johan Askling, Ruxandra Ionescu, Michael J. Nissen, Karel Pavelka, Carlos Sanchez-Piedra, Servet AkarJoseph Sexton, Matija Tomsic, Helena Santos, Marco Sebastiani, Jenny Österlund, Arni Jon Geirsson, Gary Macfarlane, Irene van der Horst-Bruinsma, Stylianos Georgiadis, Cecilie Heegaard Brahe, Lykke Midtbøll Ørnbjerg, Merete Lund Hetland, Mikkel Østergaard

Research output: Contribution to journalArticleAcademicpeer-review

34 Citations (Scopus)


OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. METHODS: Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)). RESULTS: We included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82%/72%, with significant (p<0.001) differences between the registries (6-month: 70-93%, 12-month: 53-86%) and across number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/73%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs: 78%/66%). Overall 6-month/12-month BASDAI<4 were observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50 in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46% and ASDAS-MI in 25%/26% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-naïve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness. CONCLUSIONS: In this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12 months of treatment were high. Secukinumab effectiveness was consistently better for bionaïve patients, independent of time since diagnosis and differed across the European countries.

Original languageEnglish
Issue number3
Publication statusPublished - 1 Sept 2020


  • DMARDs (biologic)
  • Outcomes research
  • Spondyloarthritis

Cite this